Broyhill Asset Management Purchases New Position in Fresenius Medical Care AG (NYSE:FMS)

Broyhill Asset Management bought a new stake in Fresenius Medical Care AG (NYSE:FMS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 150,686 shares of the company's stock, valued at approximately $3,412,000. Fresenius Medical Care makes up approximately 3.0% of Broyhill Asset Management's investment portfolio, making the stock its 10th biggest holding.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Venturi Wealth Management LLC raised its holdings in shares of Fresenius Medical Care by 8.4% during the 4th quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company's stock valued at $129,000 after purchasing an additional 441 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Fresenius Medical Care by 5.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,278 shares of the company's stock worth $210,000 after acquiring an additional 442 shares in the last quarter. MML Investors Services LLC raised its stake in shares of Fresenius Medical Care by 5.3% in the 3rd quarter. MML Investors Services LLC now owns 15,019 shares of the company's stock valued at $320,000 after acquiring an additional 753 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in Fresenius Medical Care by 192.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company's stock worth $28,000 after purchasing an additional 806 shares during the last quarter. Finally, DAVENPORT & Co LLC boosted its position in Fresenius Medical Care by 1.5% during the fourth quarter. DAVENPORT & Co LLC now owns 58,147 shares of the company's stock worth $1,316,000 after purchasing an additional 862 shares during the period. 8.37% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Truist Financial boosted their price objective on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a "hold" rating in a research note on Monday, January 6th. StockNews.com upgraded shares of Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th.

Fresenius Medical Care Stock Performance

FMS stock traded down $1.10 on Friday, reaching $23.65. 445,019 shares of the company were exchanged, compared to its average volume of 317,925. The firm has a market capitalization of $13.88 billion, a PE ratio of 19.54, a PEG ratio of 0.76 and a beta of 0.93. Fresenius Medical Care AG has a 12 month low of $17.93 and a 12 month high of $25.96. The stock's fifty day moving average price is $23.94 and its 200 day moving average price is $22.88. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.